Literature DB >> 26598506

TRPC3 channel confers cerebrovascular remodelling during hypertension via transactivation of EGF receptor signalling.

Mi Wang1, Yong-Bo Tang2, Ming-Ming Ma2, Jing-Hui Chen3, Chang-Ping Hu4, Shui-Ping Zhao5, Dao-Quan Peng5, Jia-Guo Zhou2, Yong-Yuan Guan2, Zheng Zhang6.   

Abstract

AIMS: Ionic perturbation in vascular smooth muscle cells contributes to cerebrovascular remodelling in the setting of hypertension, but the role of transient receptor potential (TRP) channel superfamily remains unknown. The present study was conducted to define the contribution of TRP channels to cerebrovascular remodelling. METHODS AND
RESULTS: By integrating quantitative PCR, western blotting, patch clamping, and Ca(2+) imaging, we identified TRP channel, subfamily canonical, member 3 (TRPC3) as the channel subtype most considerably elevated in basilar arteries of two-kidney, two-clip stroke-prone hypertensive rats. Importantly, administration of pyrazole 3 (Pyr3), a TRPC3 channel blocker, attenuated cerebrovascular remodelling. During hypertension, epidermal growth factor receptor (EGFR) was transactivated, as evidenced by marked EGFR phosphorylation, increased pro-HB-EGF shedding, and elevated activity of ADAM17 (HB-EGF sheddase). ADAM17 activity was increased owing to enhanced activation rather than elevated expression. Remarkably, Pyr3 treatment suppressed EGFR transactivation in hypertension. In proliferating basilar artery smooth muscle cells or basilar arteries of hypertensive rats, co-immunoprecipitation assay revealed an interaction between TRPC3 and ADAM17 upon Ang II stimulation.
CONCLUSION: Collectively, we demonstrated that enhanced EGFR transactivation, due to increased TRPC3 expression and functional coupling of TRPC3/ADAM17, resulted in cerebrovascular remodelling. Therefore, TRPC3-induced EGFR transactivation may be therapeutically exploited to prevent hypertension-induced cerebrovascular remodelling. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2015. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Angiotensin II; Cerebrovascular remodelling; Hypertension; TRPC3

Mesh:

Substances:

Year:  2015        PMID: 26598506     DOI: 10.1093/cvr/cvv246

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  6 in total

1.  Differences in TRPC3 and TRPC6 channels assembly in mesenteric vascular smooth muscle cells in essential hypertension.

Authors:  Inés Álvarez-Miguel; Pilar Cidad; M Teresa Pérez-García; José Ramón López-López
Journal:  J Physiol       Date:  2016-12-29       Impact factor: 5.182

2.  Upregulation of Transient Receptor Potential Canonical Type 3 Channel via AT1R/TGF-β1/Smad2/3 Induces Atrial Fibrosis in Aging and Spontaneously Hypertensive Rats.

Authors:  Rongfang He; Juan Zhang; Dan Luo; Yiyan Yu; Tangting Chen; Yan Yang; Fengxu Yu; Miaoling Li
Journal:  Oxid Med Cell Longev       Date:  2019-11-23       Impact factor: 6.543

Review 3.  Role of store-operated Ca2+ entry in cardiovascular disease.

Authors:  Ting Lu; Yihua Zhang; Yong Su; Dayan Zhou; Qiang Xu
Journal:  Cell Commun Signal       Date:  2022-03-18       Impact factor: 5.712

4.  Involvement of transient receptor potential channels in ocular diseases: a narrative review.

Authors:  Tian-Jing Yang; Yang Yu; Jing-Yi Yang; Jin-Jing Li; Jun-Ya Zhu; João Alexandre Cardoso Vieira; Qin Jiang
Journal:  Ann Transl Med       Date:  2022-08

5.  Knockdown of Chloride Channel-3 Inhibits Breast Cancer Growth In Vitro and In Vivo.

Authors:  Fang-Min Zhou; Yun-Ying Huang; Tian Tian; Xiao-Yan Li; Yong-Bo Tang
Journal:  J Breast Cancer       Date:  2018-06-20       Impact factor: 3.588

Review 6.  Morphological and Functional Characteristics of Animal Models of Myocardial Fibrosis Induced by Pressure Overload.

Authors:  Yuejia Ding; Yuan Wang; Qiujin Jia; Xiaoling Wang; Yanmin Lu; Ao Zhang; Shichao Lv; Junping Zhang
Journal:  Int J Hypertens       Date:  2020-01-31       Impact factor: 2.420

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.